Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2022 08:05 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market...
April 21, 2022 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
March 24, 2022 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study...
March 22, 2022 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology

New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers Efficacy of Trudhesa After Variety of Acute Therapies Post Hoc Pivotal Trial Data...
February 28, 2022 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
January 18, 2022 08:05 ET | Source: Impel NeuroPharma

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...
November 15, 2021 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted...
November 09, 2021 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
November 08, 2021 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
September 28, 2021 08:30 ET | Source: Impel NeuroPharma

Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine

Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space ...